UNSPSC 51384622: Praxadine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C16H14N2O6S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 24PUW23GRX, chemically known as phthalanilic acid, 4-(acetylsulfamoyl)- but more generally known as phthalylsulfacetamide, which bears U.S. National Institutes of Health Compound Identifier 8574. The European Medicines Agency schedules Phthalylsulfacetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35390.

SMILES: S(=O)(=O)(NC(=O)C)C1CCC(NC(=O)C2C(CCCC2)C(=O)O)CC1.

UNSPSC 51384622 Praxadine, a Commodity code, covers pharmaceutical products and related delivery systems that state and local governments procure to support public health and community health initiatives. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions including Oregon). These buyers source through a mix of competitive bidding processes, RFPs with formal evaluation criteria, and market research RFIs to inform future procurement strategy.

Activity in this code concentrates in Florida and the Upper Midwest, with Texas representing exploratory activity at the state health agency level. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 26, 2023 (note: the source date appears internally inconsistent); the contract includes a two-year initial term with a one-year renewal option and requires E-Verify compliance and specific insurance coverage including commercial general liability. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, closing March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act certification. The Texas HHS Commission issued RFI HHS0017013 in March 2026 (response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling potential future formal procurement in that state.